3-(4-phenoxyphenyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine
330786-24-8Nc1ncnc2n[nH]c(-c3ccc(Oc4ccccc4)cc3)c12YYVUOZULIDAKRN-UHFFFAOYSA-N330786-24-8DTXSID401380342CHEMBL1242204安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
Danger
H301 (25%): Toxic if swallowed [Danger Acute toxicity, oral]
P261, P264, P264+P265, P270, P271, P273, P280, P301+P316, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P391, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 4 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
説明5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMine, also known as ibrutinib N-2, is a light brown solid. It can be prepared from 3-Iodo-1H-pyrazolo[3,4-d]pyrimidin-4-amine and 4-phenoxybenzeneboronicacid by Suzuki coupling reaction[1]. Ibrutinib N-2 is often used in the preparation of the marketed drug PCI-32765 (IMBRUVICAVR)[2]. PCI-32765 is aIbrutinib -BTK inhibitor and can be used as an anticancer drug to treat B cell cancers like mantle cell lymphoma and chronic lymphocytic leukemia.
使用As Ibrutinib intermediates, 5-(4-phenoxyphenyl)-7H-pyrrolo[2,3-d]pyriMidin-4-ylaMine can be used as organic synthesis intermediates and pharmaceutical intermediates, mainly used in laboratory research and development and chemical production processes.
現在のフィルター条件では反応記録がありません。
読み込み中…